[8-K] BioCardia, Inc. Warrant Reports Material Event

Rhea-AI Filing Summary

BioCardia (NASDAQ:BCDA) filed an 8-K announcing the grant of US Patent No. 12,311,127 titled "Radial and Trans-endocardial Delivery Catheter" by the United States Patent Office. The patent strengthens the company's intellectual property portfolio in medical device technology. The filing includes the announcement via press release and standard exhibits.

Positive

• Granted new US Patent strengthening intellectual property portfolio
• Patent covers strategic medical device technology in catheter delivery systems

Negative

• None.

Insights

Medical Technology Analyst

Patent grant strengthens BioCardia's competitive position in catheter delivery systems for cardiovascular applications.

The newly granted patent for radial and trans-endocardial delivery catheter technology represents a significant addition to BioCardia's intellectual property portfolio. This patent likely provides protection for novel catheter design features that could be crucial for precise delivery of therapeutic agents or devices to the heart. The technology appears focused on improving delivery methods, which is essential for cardiovascular procedures and could enhance the company's market position in interventional cardiology.

false 0000925741 0000925741 2025-06-25 2025-06-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2025

BIOCARDIA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38999		23-2753988
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

320 Soquel Way
Sunnyvale, California 94085

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 226-0120

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	BCDA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01   Other Events.

On June 25, 2025, BioCardia, Inc. (the “Company”) issued a press release announcing that the United States Patent Office has granted US Patent No. 12,311,127 titled “Radial and Trans-endocardial Delivery Catheter.” A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		BioCardia, Inc. press release dated June 25, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCARDIA, INC.

/s/ Peter Altman, Ph.D.

Peter Altman, Ph.D.

President and Chief Executive Officer

Date: June 25, 2025

FAQ

What patent did BioCardia (BCDA) receive from the US Patent Office?

BioCardia received US Patent No. 12,311,127 titled "Radial and Trans-endocardial Delivery Catheter" from the United States Patent Office.

When was BioCardia's new patent announced?

BioCardia announced the patent grant on June 25, 2025 via press release.

Who signed the 8-K filing for BioCardia?

The 8-K was signed by Peter Altman, Ph.D., President and Chief Executive Officer of BioCardia.